
Trafigura sees oil at $60 thanks to vaccines
Commodity trading giant Trafigura expects a strong rebound in oil demand next year thanks to mass vaccinations, which will push crude oil prices to $55-60 a barrel, Argus Media reported,
Commodity trading giant Trafigura expects a strong rebound in oil demand next year thanks to mass vaccinations, which will push crude oil prices to $55-60 a barrel, Argus Media reported,
Trafigura, one of a clutch of privately held oil trading firms, reminded the world last week how good it is to be an oil trader when oil markets are imploding.
President Energy’s Peter Levine discusses their latest operation & production update, whether they’ll need to fundraise for drilling wells & more infrastructure, and an update on operations in Paraguay in this exclusive interview with DirectorsTalk.
Oil rose on Friday, adding to sharp gains overnight that saw Brent top $50 for the first time since March, as the rollout of coronavirus vaccination programmes fed hopes that
President Energy plc (LON:PPC) CEO and Chairman Peter Levine joins DirectorsTalk to discuss its operation and production update. Peter talks us through the highlights, explains what it means for the company,
The oil markets have staged a dramatic rally since early November, with WTI breaking out of a range between the high $30’s and low $40’s for the first time since
President Energy plc (LON:PPC), the energy company with a diverse portfolio of production and exploration assets, has announced an operations and production update in relation to its activities across the Group.
Oil prices jumped around 2% on Friday, heading for a fifth week of gains, as major producers agreed on a compromise to continue some cuts to production to cope with
President Energy’s Peter Levine discusses their latest drilling update and what we can expect in terms of news flow in the coming weeks and months in this exclusive interview with DirectorsTalk.
A surge in COVID-19 cases in the winter season will not derail the oil market rebalancing driven mainly by vaccine progress, Goldman Sachs said in a note, adding that it